Circadian_infusion_of_floxuridine_in_patients_with_metastatic_renal_cell_carcinoma._A_total_of_42_patients_with_metastatic_renal_cell_carcinoma_received_floxuridine_infusion_for_14_days_at_monthly_intervals._The_drug_was_delivered_via_an_external_programmable_pump_on_a_time-modified_or_circadian_schedule;_the_highest_dose_of_68%_was_given_between_3_and_9_p.m._Of_the_42_patients_25_(60%)_had_undergone_prior_nephrectomy._Of_the_40_evaluable_patients_4_(10%,_95%_confidential_interval_3_to_24%)_achieved_a_partial_response:_3_of_the_4_had_undergone_prior_nephrectomy,_while_1_had_undergone_renal_angioinfarction._Another_4_patients_(10%)_had_responses_at_metastatic_sites_but_no_response_in_the_primary_kidney_tumor._The_median_duration_of_response_for_these_2_groups_of_patients_was_65_and_27_weeks,_respectively,_and_the_most_responsive_site_was_the_lungs._The_treatment_was_generally_well_tolerated_and_could_be_administered_on_an_outpatient_basis._Our_study_confirms_the_limited_but_definite_activity_of_floxuridine_infused_on_a_circadian_schedule_in_patients_with_metastatic_renal_cell_carcinoma._We_observed_responses_in_metastasis_equally_in_patients_with_or_without_prior_nephrectomy.